Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients - Wikidata - awgldk - TriplyDB

Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients

Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients

http://www.wikidata.org/entity/Q34247688

about

Cryptococcal meningitis treatment strategies in resource-limited settings: a cost-effectiveness analysis Cryptococcus-Related Immune Reconstitution Inflammatory Syndrome (IRIS): Pathogenesis and its Clinical Implications Paucity of initial cerebrospinal fluid inflammation in cryptococcal meningitis is associated with subsequent immune reconstitution inflammatory syndrome LATERAL FLOW ASSAY FOR CRYPTOCOCCAL ANTIGEN: AN IMPORTANT ADVANCE TO IMPROVE THE CONTINUUM OF HIV CARE AND REDUCE CRYPTOCOCCAL MENINGITIS-RELATED MORTALITY Host immunity to Cryptococcus neoformans Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungal Integrated therapy for HIV and cryptococcosis HIV-Associated Cryptococcal Meningitis: Bridging the Gap Between Developed and Resource-Limited Settings Increased permeability of blood-brain barrier is mediated by serine protease during Cryptococcus meningitis A prospective descriptive study of cryptococcal meningitis in HIV uninfected patients in Vietnam - high prevalence of Cryptococcus neoformans var grubii in the absence of underlying disease.Treatment of cryptococcal meningitis in KwaZulu-Natal, South Africa.Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi A high-throughput screening assay for fungicidal compounds against Cryptococcus neoformans.Cryptococcal meningitis: epidemiology and therapeutic options.Predictors of neurocognitive outcomes on antiretroviral therapy after cryptococcal meningitis: a prospective cohort study.High-dose fluconazole in combination with amphotericin B is more efficient than monotherapy in murine model of cryptococcosis.Outcomes of cryptococcal meningitis in antiretroviral naïve and experienced patients in South Africa.Very low levels of 25-hydroxyvitamin D are not associated with immunologic changes or clinical outcome in South African patients with HIV-associated cryptococcal meningitis.Radioimmunotherapy is more effective than antifungal treatment in experimental cryptococcal infection.Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis.Recent advances in management of cryptococcal meningitis: commentary.Comparison and temporal trends of three groups with cryptococcosis: HIV-infected, solid organ transplant, and HIV-negative/non-transplant Antifungal clinical trials and guidelines: what we know and do not know Efficient phagocytosis and laccase activity affect the outcome of HIV-associated cryptococcosis.A repurposing approach identifies off-patent drugs with fungicidal cryptococcal activity, a common structural chemotype, and pharmacological properties relevant to the treatment of cryptococcosis Long term 5-year survival of persons with cryptococcal meningitis or asymptomatic subclinical antigenemia in Uganda.The Celecoxib Derivative AR-12 Has Broad-Spectrum Antifungal Activity In Vitro and Improves the Activity of Fluconazole in a Murine Model of Cryptococcosis.An update on Cryptococcus among HIV-infected patients.Radiolabeled antibodies for therapy of infectious diseases.Cryptococcus neoformans as a Model for Radioimmunotherapy of Infections Estrogen receptor antagonists are anti-cryptococcal agents that directly bind EF hand proteins and synergize with fluconazole in vivo.Comparison of flucytosine and fluconazole combined with amphotericin B for the treatment of HIV-associated cryptococcal meningitis: a systematic review and meta-analysis.Cytokine profiles at admission can be related to outcome in AIDS patients with cryptococcal meningitis Combination Versus Monotherapy for the Treatment of HIV Associated Cryptococcal Meningitis Rapid microscopy and use of vital dyes: potential to determine viability of Cryptococcus neoformans in the clinical laboratory.Comparative effectiveness of induction therapy for human immunodeficiency virus-associated cryptococcal meningitis: a network meta-analysis.Structure-activity relationships for the antifungal activity of selective estrogen receptor antagonists related to tamoxifen Treatment principles for Candida and Cryptococcus.Genotypic Diversity Is Associated with Clinical Outcome and Phenotype in Cryptococcal Meningitis across Southern Africa AMBITION-cm: intermittent high dose AmBisome on a high dose fluconazole backbone for cryptococcal meningitis induction therapy in sub-Saharan Africa: study protocol for a randomized controlled trial.

P2860

Q21144604-DE82881B-6E2D-409D-A5ED-08E7B5BA3C05 Q24629367-585FFE32-E49D-47B2-893D-F97A51A6F3D5 Q24630287-F0544378-DE49-41A3-9B19-9EA4B8F59708 Q26783210-1A17B5AD-48AB-4E57-B053-10E42C5EB72A Q26823438-7F9899A3-A310-45F4-8DE2-4147791410BD Q27012487-9BDB5177-7B3A-4476-A3A8-5807737C3B06 Q28077707-165B4ABF-B9F9-461C-96F5-102E0981179A Q28078958-D6FA3E55-AC29-4907-BC8F-61A6FC227B2D Q28305427-396D5AA8-44FB-4424-812F-C44774672666 Q30495712-2B1232F4-0DB6-4273-9848-A65DA16CF381 Q33523050-8896E575-6017-41BD-A3AE-CA392FC941AE Q33588561-1FB6B1DB-4A7C-4A9D-99A8-22EE5BB44194 Q33595937-0B7C3E7F-6749-43CF-A9C2-3AFA80AFFC22 Q33633343-4F525AD0-AAC4-4943-B3AD-7D3BE88831EC Q33663591-47BCB1B9-CA36-4B3A-ADE4-F208EE4F5F9A Q33875911-21CBBA45-83E7-41A2-BF5F-A608F844E904 Q33888707-28044A39-F020-4723-916E-FE0F19F268C7 Q33953918-6C77300F-7366-4D92-9E5A-6F19150CEF8B Q33996459-FD8019C9-CF04-4E6D-A6B2-7410D0864A8C Q34024416-17F78F05-9296-47F9-9FE7-BC370C1BACEA Q34389849-C610DA59-3DE5-42AB-BFED-359F9C05F802 Q34399223-E7DA445B-4EE1-459C-ADD2-6F638673B6EC Q34400255-2CCA158B-BE73-4010-84A4-66B9B6339C5A Q34415736-34CFA448-1674-45B5-A52D-8475BFE7FDDD Q34513852-D205E43B-DAE5-40EA-891B-02C894436A84 Q34516367-4A9859E2-D418-44EE-90B2-AD8C35F604EA Q34540684-C4B2E22E-8940-4B72-9F3E-721D582654A0 Q34625655-9FAFE2CE-FE01-49D8-9BD6-5DEDC4A3D8AD Q34955947-5C6FB0FF-FF75-4760-8FA8-767CD69D665C Q35072954-BB341C6B-6FBA-4864-A584-AF5DB110EE47 Q35092521-136CDC14-96AA-4916-A92B-9979A960D051 Q35097032-13415063-DF3E-4B21-AFC9-54F454DC7229 Q35208706-826427EF-E992-434D-8B13-BED57D063ED7 Q35230534-3DA24F97-7BCE-4EC0-A739-AE5C367816CC Q35549784-AA41A7CC-5BCC-4AB9-A18D-ACBBBA823458 Q35628245-566F666A-F226-43FF-BDEE-2C2B4DA7EBB9 Q35643319-6432DD5D-E4D6-4CAA-BC4E-F708E22A6219 Q35664186-3C922D55-60BF-4158-8E82-EDE6BDD7BB38 Q35674504-2377855F-BAE2-4474-BC66-116A63437148 Q35776693-E075DDBC-57E9-4DF6-93B0-4058A2512BE2

P2860

Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients

http://www.wikidata.org/entity/Q34247688

description

2009 nî lūn-bûn

@nan

2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Independent association betwee ...... ombined cohort of 262 patients

@ast

Independent association betwee ...... ombined cohort of 262 patients

@en

Independent association betwee ...... ombined cohort of 262 patients

@nl

type

label

Independent association betwee ...... ombined cohort of 262 patients

@ast

Independent association betwee ...... ombined cohort of 262 patients

@en

Independent association betwee ...... ombined cohort of 262 patients

@nl

prefLabel

Independent association betwee ...... ombined cohort of 262 patients

@ast

Independent association betwee ...... ombined cohort of 262 patients

@en

Independent association betwee ...... ombined cohort of 262 patients

@nl

P1433

Q34247688-F791224B-3DD6-487C-98DD-85DECAE8EC93

P1476

Q34247688-D0574456-7C07-4332-BEBA-29DF558368B9

P2093

Q34247688-084EE027-46A9-47D6-928A-39243DC5EB12

Q34247688-0B0D3B06-E360-4335-9BEA-692A49FF79B0

Q34247688-3F9B42E2-41F4-4144-82BE-5788949E5F9B

Q34247688-4E352A75-1172-4797-BE45-3C90C107D58D

Q34247688-6522CA2D-0F24-46EE-A81C-DA62D5CF4933

Q34247688-770A7306-49E7-48E7-A35F-F704CE476751

Q34247688-82C54D4B-D391-4E54-9379-687915A632B3

P2860

Q34247688-1219A2C2-C017-49F8-8F20-F78CDA2A5716

Q34247688-17AEC002-0053-4287-B7C2-000ED725FB47

Q34247688-28896FB1-04B5-410C-BDBD-7F67053705A2

Q34247688-4FFC4A0A-63CD-4012-B2BF-3E1CF1D048E7

Q34247688-871FDA06-9878-4870-AE77-AADEC2E8DB6D

Q34247688-957A9BF0-2ED6-4ED0-8D42-6D2C11A5F554

Q34247688-96DAA9D4-9658-4FC0-930F-811803340D9A

Q34247688-A69FA99C-CCC2-4DA0-B2BF-40E56A11358F

Q34247688-B3AC70F0-85CA-427F-9609-3E03FA0603F2

Q34247688-C0E7C4DF-6203-412F-BFAC-7C7B1FD9D926

P304

Q34247688-E31CC273-39AA-462E-9F3E-CA00954CA3B6

P31

Q34247688-C6B7C559-B34C-4088-9895-BA6464163EFC

P356

Q34247688-0442A649-C7D4-480A-A18C-D5F07AF8A1DD

P407

Q34247688-7BA50560-12E7-49C8-BEBD-5D123C22D5F5

P433

Q34247688-362BD07D-A19E-4C66-8C53-13D060080D79

P478

Q34247688-4340CB96-1801-4BAE-94D8-E2F9FF0DB4B2

P50

Q34247688-1C7720E3-4AB8-4F4D-AA05-802729229193

Q34247688-2B12D108-C36D-4DCE-9D64-39C6CB9B46AB

Q34247688-3AB074EC-8900-4E6B-81DF-63C93FAC7477

Q34247688-48FA522D-9E48-4272-B3AE-1F81EDB9A422

Q34247688-4A558E17-5ACC-454F-B532-17776B5C9D10

Q34247688-6BFB867C-036D-462B-A2FD-B1AD68EA7F0E

Q34247688-B127C9C4-1C5E-40E9-BEB1-0487219E9CBA

Q34247688-D6E87E58-EF7F-41B5-BA85-74AB3BA41354

Q34247688-EA3F95B5-A891-4522-A626-716F87D91E4D

Q34247688-FA995AE8-9EAC-4FFA-8B67-17EB7015DAF8

P577

Q34247688-5B5BF4EA-3A72-43CD-B825-1F765CA3B47C

P5875

Q34247688-F58AA43E-569E-4B61-8C72-E6F098380375

P698

Q34247688-A034503C-8078-4A11-B54A-8E39F960FD7C

P921

Q34247688-2C4ED99D-2E87-40EE-9F8F-20570F37ACCC

Q34247688-94EBE87D-B692-40AE-8C77-78F068C69937

P932

Q34247688-199A2D71-6AB0-4ED5-AB62-18F34A5B2C9E

P356

P1433

Clinical Infectious Diseases

P1476

Independent association betwee ...... ombined cohort of 262 patients

@en

P2093

Angela Loyse

http://www.w3.org/2001/XMLSchema#string

Annemarie E Brouwer

http://www.w3.org/2001/XMLSchema#string

Conrad Muzoora

http://www.w3.org/2001/XMLSchema#string

Kabanda Taseera

http://www.w3.org/2001/XMLSchema#string

Kevin Rebe

http://www.w3.org/2001/XMLSchema#string

Nicky Longley

http://www.w3.org/2001/XMLSchema#string

Tihana Bicanic

http://www.w3.org/2001/XMLSchema#string

P2860

Outcome of AIDS-associated cryptococcal meningitis initially treated with 200 mg/day or 400 mg/day of fluconazole

Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda.

Analysis of serial measurements in medical research.

T cell cytokine responses in persons with tuberculosis and human immunodeficiency virus infection.

Statistical evaluation of biomarkers as surrogate endpoints: a literature review.

Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy.

Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults.

Causes of death in a rural, population-based human immunodeficiency virus type 1 (HIV-1) natural history cohort in Uganda.

Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial.

Morbidity and mortality in South African gold miners: impact of untreated disease due to human immunodeficiency virus.

P304

702-709

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/604716

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

49

http://www.w3.org/2001/XMLSchema#string

P50

Nicholas John White

Wirongrong Chierakul

Direk Limmathurotsakul

Linda-Gail Bekker

Kasia Stepniewska

Graeme Meintjes

Joseph N. Jarvis

Thomas Harrison

P577

2009-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26678450

http://www.w3.org/2001/XMLSchema#string

P698

19613840

http://www.w3.org/2001/XMLSchema#string

P921

P932

2965403

http://www.w3.org/2001/XMLSchema#string